Financial Health Assessment: RED INDUSTRIES (STOKE) LIMITED

1. Financial Health Score: A-

Explanation: The patient is exhibiting exceptional structural strength and has successfully undergone a massive detoxification of its liabilities. However, a chronic case of low liquidity ("thin blood") prevents a perfect score. The business is fundamentally robust, heavily supported by its corporate parentage, but needs to ensure its cash reserves are sufficient to handle unexpected shocks without relying entirely on external lifelines.

2. Key Vital Signs

• Net Assets (The Heartbeat): £10.61M (2025)
  • Interpretation: This is a tremendously strong pulse. The company’s net assets have surged from £4.45M in 2023 to over £10.6M in 2024/2025. This indicates a major capital injection, restructure, or significant profit retention that has drastically bolstered the financial constitution of the business.
• Total Liabilities (Cholesterol Levels): £4.68M (2025)
  • Interpretation: Excellent. The company has cleared out nearly half of its total liabilities from the 2023 peak of £8.97M. This debt diet has vastly improved the financial circulatory system, reducing the burden of external obligations.
• Cash Position (Hydration Levels): £78,220 (2025)
  • Interpretation: Dangerously low. For a company of this size, holding less than £80k in cash is like an elite athlete functioning on a thimble of water. While the patient is currently functioning, any sudden operational shock could cause severe dehydration.
• Turnover (Metabolic Rate): £18.7M (2025)
  • Interpretation: A slight slowdown. Revenue dropped by 2.6% from £19.2M in 2024. This is a mild symptom of the current economic climate and inflation, but not yet a cause for alarm.

3. Diagnosis

Primary Condition: Robust Structural Health with Chronic Liquidity Anemia

The financial data reveals a business that has undergone a remarkable transformation. Between 2021 and 2023, the company carried high liabilities against modest net assets—a patient carrying too much weight with a weakened immune system. However, the 2024/2025 period shows a dramatic recovery. The near-doubling of net assets and the halving of total liabilities suggest a significant internal reorganization, likely supported by the parent companies (Red Industries Holdings Limited and Red Industries Limited) who hold over 75% control.

Despite this excellent structural recovery, the company suffers from "liquidity anemia." A cash balance of £78k on a £16M asset base is exceptionally thin. The directors note that the company retains "suitably adequate finance facilities, including an agreed invoice financing facility," which acts as a vital IV drip keeping the cash flow stable. The auditor's unqualified opinion and going concern validation confirm that this IV drip is currently reliable, but the underlying dependency on external financing remains a systemic vulnerability.

The slight drop in turnover and gross profit in the first half of 2025 are transient symptoms—likely a mild infection from the broader economic environment—but management has responded well by cutting administrative expenses by £400k, acting as a preventative antibiotic to protect the bottom line.

4. Recommendations

• Rebuild Cash Reserves (Hydration Therapy): With cash hovering around £78k, the company is heavily reliant on invoice financing. While effective, this creates dependency. Aim to build a minimum cash buffer equivalent to 1-2 months of operating expenses to protect against sudden disruptions in the waste management supply chain.
• Monitor the Top Line (Metabolic Support): The 2.6% drop in turnover needs to be closely watched. While efficiency savings (the £400k admin cut) are excellent preventative medicine, they cannot be cut indefinitely. Focus on volume recovery in 2026 to ensure the revenue "metabolism" remains healthy.
• Leverage the Balance Sheet (Physical Therapy): With a vastly strengthened balance sheet (high net assets, lower liabilities), the company is in a prime position to negotiate better terms. Whether that means securing lower interest rates on debt, renegotiating supplier terms, or refinancing existing facilities, use this newly acquired structural strength to your advantage.
• Inflation Vaccination: The directors rightly identify inflation as an ongoing risk. Continue to pass justified price increases to the customer base to ensure margins are not eroded by rising supply chain and wage costs.